In contrast, we found that strong/intense membranous/cytoplasmic immunoreactivity of LY6G6D was less frequent in mucinous carcinomas than in non-mucinous carcinomas CRC, (18–35%) (p < 0.05) (Fig. 3A). Here, LY6G6D is linked to mucinous adenocarcinoma.